Showing results (1-10 of 222) with videos related to
Sort By:
Pageof 23
Current Opinion in Lipidology|July 8, 2011
Susceptibility of LDL and its subfractions to glycationHandrean Soran, Paul N DurringtonCurrent Opinion in Lipidology|September 9, 2022
What should be the goal of cholesterol-lowering treatment? A quantitative evaluation dispelling guideline mythsPaul N Durrington, Bilal Bashir, Handrean SoranEuropean Journal of Preventive Cardiology|September 10, 2016
Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treatHandrean Soran, Safwaan Adam, Paul N DurringtonFrontiers in Cardiovascular Medicine|March 6, 2023
Paraoxonase 1 and atherosclerosisPaul N Durrington, Bilal Bashir, Handrean SoranAtherosclerosis|October 2, 2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease riskHandrean Soran, Safwaan Adam, Paul N DurringtonAntioxidants (Basel, Switzerland)|April 29, 2025
How Does HDL Participate in Atherogenesis? Antioxidant Activity Versus Role in Reverse Cholesterol TransportPaul N Durrington, Bilal Bashir, Handrean SoranCurrent Opinion in Lipidology|July 1, 2014
The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapyHandrean Soran, Jonathan D Schofield, Paul N DurringtonFrontiers in Pharmacology|November 4, 2015
Antioxidant properties of HDLHandrean Soran, Jonathan D Schofield, Paul N DurringtonCurrent Opinion in Lipidology|May 11, 2018
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targetsHandrean Soran, Jan Hoong Ho, Paul N DurringtonEuropean Heart Journal|August 6, 2015
Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatmentHandrean Soran, Jonathan D Schofield, Paul N DurringtonPageof 23